Core Viewpoint - Marimaca Copper Corp. has secured binding commitments for a brokered placement of 8,247,423 new Chess Depositary Interests (CDI) at a price of A$9.70 per CDI, resulting in gross proceeds of approximately A$80,000,000 or C$72,080,000 [1][2] Group 1 - The placement received strong support from new institutional and sophisticated investors, with demand significantly exceeding the targeted amount [2] - The net proceeds from the placement will be allocated for exploration at the Pampa Medina Project, detailed design and engineering at the Marimaca Oxide Deposit, and general corporate purposes [3] - The CDIs will be issued under an ASX Listing Rule 7.1 waiver, with completion expected around September 11, 2025, subject to regulatory approvals [4] Group 2 - Marimaca is focused on its 100%-owned Marimaca Copper Project and surrounding exploration properties located in the Antofagasta Region, Chile [7] - The Marimaca Copper Project includes the Marimaca Oxide Deposit, and the company is progressing through a Definitive Feasibility Study led by Ausenco Chile Ltda [8]

Core Insights - The Launch-HTN trial of lorundrostat, a novel aldosterone synthase inhibitor, shows significant blood pressure reductions in diverse high-risk patient populations with uncontrolled hypertension [1][2][3] - The trial enrolled 1,083 participants, making it the largest global Phase 3 trial for uncontrolled or resistant hypertension [6][12] - Lorundrostat demonstrated a favorable safety and tolerability profile, with no new safety signals observed [5][8] Company Overview - Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for hypertension and related conditions driven by dysregulated aldosterone [1][15] - The company plans to file a New Drug Application (NDA) for lorundrostat in late 2025 or early 2026 [9] Trial Details - The Launch-HTN trial utilized automated office blood pressure measurements and allowed participants to continue existing antihypertensive medications [6][12] - Key demographics of the trial included 29% Black/African American participants, 41% aged 65 or older, and 63% with obesity [2][3] Efficacy Results - Lorundrostat 50 mg showed statistically significant reductions in blood pressure across various subgroups, including a 16.9 mmHg reduction at Week 6 and a 19.0 mmHg reduction at Week 12 [7][12] - The trial results indicated consistent blood pressure lowering effects across high-risk subgroups, addressing a critical unmet medical need [3][4] Safety Profile - The safety outcomes were favorable, with adverse events generally mild or moderate, and a very low incidence of serious drug-related adverse events [5][8] - No significant suppression of cortisol production was observed, and electrolyte changes were modest and reversible [8] Market Context - Hypertension is a leading modifiable risk factor for cardiovascular disease, contributing to over 685,000 deaths in the U.S. in 2022 [10] - Less than 50% of hypertension patients achieve their blood pressure goals with current medications, highlighting the need for new treatments like lorundrostat [11]

Company Overview - Legacy Education Inc. is a leading provider of career-focused education and training, primarily in the healthcare field, offering certificates and degrees in various disciplines such as nursing, sonography, and dental assisting [4] - The company was founded in 2009 and is nationally accredited, focusing on providing high-quality, accessible, and affordable education [4] - Legacy Education aims to grow its education footprint through organic enrollment growth, new program additions, and accretive acquisitions [4] Conference Participation - Legacy Education will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8 to September 10, 2025, at the Lotte New York Palace Hotel [1] - CEO LeeAnn Rohmann will present on September 10, 2025, from 12:30 PM to 1:00 PM EST, and both the CEO and CFO Brandon Pope will be available for one-on-one meetings during the event [2] Additional Information - For more details about the conference or to request a meeting with Legacy Education's management, interested parties can contact H.C. Wainwright or visit their website [3]

~Pivotal Launch-HTN trial of novel aldosterone synthase inhibitor lorundrostat enrolled a diverse range of participants with uncontrolled or resistant hypertension~ ~Subgroups - including Black or African American adults, older adults, women, and participants with comorbid obesity – face heightened risk of poor cardiovascular outcomes and represent high unmet need~ ~Lorundrostat demonstrated significant and clinically meaningful blood pressure reductions across all participant subgroups, with a favorable sa ...

Core Insights - Robot Consulting Co., Ltd. has engaged Mr. Masaaki Seki to advise on its Ethereum investment strategy and finance objectives, effective September 1, 2025 [1][3] - Mr. Seki brings extensive experience in finance and cryptocurrency, having served as the representative director of bitFlyer Holdings and bitFlyer [2] - The company aims to expand into legal technology and the metaverse, with ongoing development of products like "Robot Lawyer" [4] Company Overview - Robot Consulting is a Japanese platform service provider focusing on human resource solutions, with a major product called "Labor Robot" that offers cloud-based HR management [4] - The company assists small and medium-sized businesses with digital transformation, grant applications, and consulting services [4] - Future developments include software and services related to legal technology and the metaverse, enhancing its service offerings [4]

Core Insights - Palisade Bio is developing PALI-2108, a first-in-class dual-acting anti-inflammatory and anti-fibrotic therapy for fibrostenotic Crohn's disease (FSCD), which currently has no approved treatments [1][3] - The company received a No Objection Letter from Health Canada for its Clinical Trial Application, allowing it to proceed with a Phase 1b clinical study [1][3] - Patient dosing is expected to begin in the second half of 2025, with topline data anticipated in the first quarter of 2026 [1][2] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on precision therapies for autoimmune, inflammatory, and fibrotic diseases [5] - The company aims to transform the treatment landscape by developing targeted therapeutics [5] Product Details - PALI-2108 is an orally administered prodrug designed for gut-restricted delivery, targeting the terminal ileum and colon [4] - The drug is activated by bacterial enzymes in the lower intestine, achieving high local tissue concentrations while minimizing systemic exposure [4] - This design aims to enhance anti-inflammatory and anti-fibrotic effects while reducing common side effects associated with systemic PDE4 inhibitors [4] Clinical Study Information - The Phase 1b study will enroll approximately 6-12 patients to evaluate safety, pharmacokinetics (PK), and pharmacodynamics (PD) [2][7] - The study will include monitoring of adverse events, laboratory tests, EKGs, and paired ileal biopsies analyzed by RNA sequencing [7] - Data from this study, along with results from previous trials in ulcerative colitis, will support the planned Phase 2 IND submission to the FDA in the first half of 2026 [3]

Group 1 - The total number of shares representing the share capital as of August 31, 2025, is 8,390,660 [1] - The gross total of voting rights is reported as 12,705,441 [1] - The net total of voting rights, which excludes shares with no voting rights, is 12,692,605 [1] Group 2 - The company is listed on Euronext Paris under Compartiment A with ISIN code FR0000031577 [2] - The company specializes in animal health, indicating a focus on veterinary products and services [2]

Group 1 - The company reported consolidated bookings of approximately $2,400,000 for August 2025, primarily driven by its Orbit Power Group (OPG) which accounted for over $1,700,000 in bookings [1][2] - A significant portion of the bookings included a follow-on order of approximately $1,000,000 for a commercial power supply used in a military application, along with an additional order of approximately $450,000 for a similar application [2] - Deliveries for the orders received during August have commenced and are expected to continue through the fourth quarter of 2026 [1] Group 2 - The company’s Simulator Products Solutions LLC (SPS) subsidiary also experienced a strong booking month and is actively bidding on several opportunities that may convert into orders in the near future [2] - The Orbit Instrument division anticipates a significant award during the current quarter related to a legacy program for the U.S. Navy, although the timing of these awards is uncertain [2] - The company remains optimistic about the breadth of opportunities and hopes for an increase in order flow for the remainder of 2025 [2] Group 3 - Orbit International Corp. is involved in the development and manufacture of custom electronic devices and subsystem solutions for military, industrial, and commercial applications [2] - The company operates production facilities in Hauppauge, NY, and Carson, CA, and its Power Group designs and manufactures a variety of power products including VPX and commercial power supplies [2]

Core Insights - NeoVolta Inc. is set to unveil its latest product, the NV16kW AC hybrid inverter, at the RE+ 2025 clean energy trade show, with general availability starting in November 2025 [1][4] - The NV16kW AC hybrid inverter is designed to provide whole-home power solutions, featuring advanced capabilities such as generator input, solar compatibility, and hybrid performance [2][4] - The product is intended to work seamlessly with NeoVolta's NV+ 10.2kWh stackable battery, creating a powerful inverter-and-battery bundle for enhanced energy independence [3][4] Product Features - The NV16kW AC hybrid inverter has a 24kW PV input and 16kW AC input capacity, with a 200A pass-through for whole-home backup [8] - It is generator-ready, solar retrofit compatible, and rated for both indoor and outdoor installations [8] - The inverter supports hybrid functionality, including AC/DC coupling and off-grid capabilities, and has received multiple certifications [8] Company Overview - NeoVolta is recognized as a leading innovator in energy storage solutions, focusing on sustainable and high-performance systems for residential and commercial applications [6] - The company aims to meet the increasing demand for efficient energy management through cutting-edge technology and strategic partnerships [6]

Core Insights - Cellectar Biosciences, Inc. is actively participating in multiple medical meetings and industry conferences in September 2025, showcasing its commitment to advancing cancer treatment [1][2][3][4][5][6]. Company Overview - Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on discovering and developing proprietary drugs for cancer treatment, both independently and through collaborations [7]. - The company aims to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to create next-generation cancer cell-targeting treatments, enhancing efficacy and safety by reducing off-target effects [8]. Product Pipeline - The company's lead assets include: - Iopofosine I 131, a PDC designed for targeted delivery of iodine-131, currently studied in Phase 2b trials for relapsed or refractory multiple myeloma and CNS lymphoma, and in a Phase 1b study for pediatric high-grade gliomas [9][10]. - CLR 121225, an actinium-225 based program targeting solid tumors with significant unmet needs, such as pancreatic cancer [9]. - CLR 121125, an iodine-125 Auger-emitting program aimed at other solid tumors, including triple-negative breast, lung, and colorectal cancers [9]. Regulatory Designations - Iopofosine I 131 has received multiple designations from the FDA, including six Orphan Drug, four Rare Pediatric Drug, and two Fast Track Designations for various cancer indications, indicating its potential significance in the oncology market [10].